Global Post Menopausal Osteoporosis Market - 2024 - 2031

Report Overview

The Global Post Menopausal Osteoporosis Market reached US$ 9.9 billion in 2023 and is expected to reach US$ 15.2 billion by 2031 growing with a CAGR of 5.4% during the forecast period 2024-2031.

Postmenopausal osteoporosis encompasses the healthcare industry's efforts to prevent, diagnose, and treat osteoporosis in women after menopause. Osteoporosis is a condition marked by diminished bone strength and an elevated risk of fractures, predominantly affecting postmenopausal women. This is primarily due to the hormonal changes that occur during menopause, which lead to a decline in bone density.

Postmenopausal osteoporosis is characterized by a significant decrease in bone mineral density (BMD), defined by the World Health Organization (WHO) as a condition where BMD is 2.5 standard deviations or more below the average for young, healthy women. This reduction in bone density primarily results from the decline in estrogen levels that occurs during menopause, which accelerates the rate of bone loss. As a consequence, postmenopausal women become more susceptible to fractures due to weakened bones.

Market Dynamics: Drivers

Rising aging population and prevalence of osteoporosis

Multiple factors drive the demand for the global post-menopausal osteoporosis market. One of the primary factors is the rising aging population and the prevalence of osteoporosis. As the global population ages, the number of postmenopausal women at risk of developing osteoporosis is increasing significantly. According to the World Health Organization (WHO) data in October 2022, the global aging population growing rapidly. In 2020, there were an estimated 1 billion people aged 60 years or older worldwide. By 2030, the global population aged 60 and above will reach 1.4 billion, representing one in six people globally. By 2050, the number of people aged 60 and over will more than double, reaching over 2.1 billion.

Osteoporosis is a prevalent condition globally, characterized by a decrease in bone mass and quality, leading to an increased risk of fractures. The World Health Organization (WHO) has established a diagnostic criterion for osteoporosis based on bone mineral density (BMD) measurements. As per the WHO, osteoporosis is diagnosed when an individual's BMD falls 2.5 standard deviations or more below the average value for young, healthy women.

According to a BMJ Yale research publication in April 2024, the prevalence of osteoporosis among women is estimated to be around 23.1%, while in men, it is significantly lower at 11.7%. This disparity can be attributed to several factors, including hormonal changes during menopause in women, which lead to accelerated bone loss.

Moreover, key palters in the industry introduce innovative products and approvals that would drive this market growth. For instance, in May 2024, Solarea Bio introduced the beta launch of Bondia, a new daily medical food aimed at helping peri- and postmenopausal women manage bone loss. This initiative is part of the company's broader goal through its consumer health brand, Journa, to raise awareness and provide effective solutions for bone health, particularly for women at heightened risk of osteoporosis due to hormonal changes associated with menopause.

Also, in December 2023, Ambio, Inc., an innovative biotechnology firm focused on developing novel peptide drugs, biosimilars, bioequivalent, and other complex generic medications, announced that the U.S. Food and Drug Administration (FDA) has approved its generic version of Forteo (teriparatide injection). This generic product will be marketed and sold by Apotex.

Restraints

Factors such as lack of awareness about postmenopausal osteoporosis, side effects & complications associated with treatment, and the high treatment costs, are expected to hamper the market.

Market Segment Analysis

The global post-menopausal osteoporosis market is segmented based on drug class, route of administration, distribution channels, and region.

The RANK ligand inhibitors (Denosumab) segment accounted for approximately 52.3% of the global post-menopausal osteoporosis market share.

The RANK ligand inhibitors (Denosumab) segment is expected to hold the largest market share over the forecast period. Denosumab, a fully human monoclonal antibody that targets and inhibits RANK ligand (RANKL), is an important treatment choice in the postmenopausal osteoporosis market. Its distinct mechanism of action and proven effectiveness in lowering fracture risk contribute to its significance as a therapeutic option.

Denosumab selectively targets and binds to RANKL, a protein essential for the development, activation, and survival of osteoclasts, which are the cells that break down bone tissue. By inhibiting RANKL, denosumab significantly reduces osteoclast activity, resulting in decreased bone resorption and increased bone mineral density (BMD). This mechanism helps to fortify bones and decrease the likelihood of fractures, a prevalent complication of osteoporosis, especially in postmenopausal women.

Moreover, key player's strategies such as partnerships & collaborations, and product approvals would drive this segment's growth. For instance, in April 2024, Sandoz announced a settlement with Amgen, resolving all patent disputes related to its denosumab biosimilars, Jubbonti and Wyost. This agreement allows Sandoz to launch these biosimilars in the U.S. market. Jubbonti is specifically approved for several indications, including treatment of postmenopausal women with osteoporosis at high risk for fractures. Treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fractures. It is increasing bone mass in women at high risk for fractures who are receiving adjuvant aromatase inhibitor therapy for breast cancer.

Also, in March 2024, Sandoz announced that the U.S. Food and Drug Administration (FDA) has approved Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz) as the first and only FDA-approved biosimilars to denosumab, which is sold under the brand names Prolia and Xgeva. Jubbonti is specifically indicated for postmenopausal women with osteoporosis who are at high risk for fractures, as well as for treating glucocorticoid-induced osteoporosis in both men and women at high risk for fractures.

Market Geographical Share

North America accounted for approximately 44.8% of the global post-menopausal osteoporosis market share

North America region is expected to hold the largest market share over the forecast period owing to the high prevalence of osteoporosis, aging population, and investment in research and development drives this market growth.

As per PRB data in January 2024, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, the proportion of this age group within the overall population is anticipated to rise from 17% to 23%.

Moreover, in this region major number of key players' presence, well-advanced healthcare infrastructure, and innovative product launches & approvals drive market growth. For instance, in November 2023, Teva Pharmaceuticals Inc., the U.S. branch of Teva Pharmaceutical Industries Ltd., announced that it had received approval for a generic version of Forteo (Teriparatide injections) in the United States. Teriparatide injections are used to treat postmenopausal women with osteoporosis who are at a high risk of fractures or who are unable to use alternative osteoporosis therapies.

Also, in January 2024, The U.S. Food and Drug Administration (FDA) approved Osteoboost, a wearable belt device developed by Bone Health Technologies, as the first non-drug, prescription treatment for postmenopausal women with osteopenia, a precursor to osteoporosis. Osteoboost is designed to deliver calibrated, low-frequency vibrations to the lumbar spine and hips, which stimulates bone growth and helps maintain bone density. The device is worn around the waist during normal daily activities involving standing and walking, with each treatment session lasting 30 minutes.

Market Segmentation

By Drug Class

Bisphosphonates

Risedronate

Alendronate

Zoledronic Acid

Ibandronate

RANK Ligand Inhibitors (Denosumab)

Selective Estrogen Receptor Modulator (SERM) (Raloxifene)

Monoclonal Antibody (Romosozumab)

Parathyroid Hormone Analog

Teriparatide

Abaloparatide

Calcitonin

Strontium

Anti-Sclerostin

Cathepsin K Inhibitors (CatK)

Others

By Route of Administration

Oral

Parenteral

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

The rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the post-menopausal osteoporosis market include Sandoz Group AG, Pfizer Inc., Amgen Inc., Novartis AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Merck & Co., Inc., Ambio Inc., and GSK plc.

Key Developments

In July 2024, Romosozumab a humanized monoclonal antibody that inhibits sclerostin, which has received approval from the United States Food and Drug Administration (FDA) for the treatment of osteoporosis in postmenopausal women at heightened risk of fractures. This anabolic therapy promotes bone formation while simultaneously reducing bone resorption. Its dual action leads to increased bone mineral density and a decrease in the risk of fractures associated with osteoporosis.

Why Purchase the Report?

To visualize the global post-menopausal osteoporosis market segmentation based on drug class, route of administration, distribution channels, and region and understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the post-menopausal osteoporosis market with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in excel consisting of key products of all the major players.

The global post-menopausal osteoporosis market report would provide approximately 62 tables, 61 figures, and 183 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies